Claudio Liguori

Dr. Claudio Liguori

Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, 100133 Rome, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
CLClaudio Liguori
Claudio Liguori
ARAndrea Romigi
Andrea Romigi
MNMarzia Nuccetelli
Marzia Nuccetelli
SZSilvana Zannino
Silvana Zannino
GSGiuseppe Sancesario
Giuseppe Sancesario
FPFabio Placidi
Fabio Placidi
Alzheimer disease (AD) is a neurodegenerative disorder predominantly characterized by progressive memory loss and gradual decline in global cognition.1 Alzheimer disease is often complicated by circadian rhythm disruption and sleep disturbances, including nightly awakenings and nonrapid eye movement (non-REM)/REM sleep dysregulation, which have a major effect on the quality of life of patients and their caregivers.2-5 Neuropathological characteristics of AD include the progressive accumulation of extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary tangles of tau proteins, which produce the dramatic loss of neurons and synapses and derange the brain’s functional and structural physiological processes. Brain regions and networks involved in the control of the sleep-wake rhythm have been also reported to be affected in AD.6 At present, Aβ1-42 and total (t-tau) and phosphorylated (p-tau) tau proteins are considered the established cerebrospinal fluid (CSF) biomarkers to support a diagnosis of AD.7-9

1 August 2020 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
CLClaudio Liguori
Claudio Liguori
MPMariangela Pierantozzi
Mariangela Pierantozzi
MSMatteo Spanetta
Matteo Spanetta
LSLoredana Sarmati
Loredana Sarmati
Novella CestaNovella Cesta
Novella Cesta
NMNicola Biagio Mercuri
Nicola Biagio Mercuri

1 February 2021 in Sleep Medicine Reviews
Verified
Journal Article
Closed access
CLClaudio Liguori
Claudio Liguori
MMMichelangelo Maestri
Michelangelo Maestri
MSMatteo Spanetta
Matteo Spanetta
FPFabio Placidi
Fabio Placidi
EBEnrica Bonanni
Enrica Bonanni
BGbiancamaria guarnieri
biancamaria guarnieri

1 April 2016 in Neurobiology of Aging
Verified
Journal Article
Closed access
CLClaudio Liguori
Claudio Liguori
MNMarzia Nuccetelli
Marzia Nuccetelli
FIFrancesca Izzi
Francesca Izzi
GSGiuseppe Sancesario
Giuseppe Sancesario
ARAndrea Romigi
Andrea Romigi
FPFabio Placidi
Fabio Placidi

25 May 2016 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
CLClaudio Liguori
Claudio Liguori
ACAgostino Chiaravalloti
Agostino Chiaravalloti
GSGiuseppe Sancesario
Giuseppe Sancesario
ASAlessandro Stefani
Alessandro Stefani
GSGiulia Sancesario
Giulia Sancesario
MPMariangela Pierantozzi
Mariangela Pierantozzi

1 December 2021 in Sleep Medicine Reviews
Verified
Journal Article
Open access
CLClaudio Liguori
Claudio Liguori
MTManuel Toledo
Manuel Toledo
SKSanjeev Kothare
Sanjeev Kothare
Anti-seizure medications (ASMs) may improve or be detrimental to sleep. A literature review (as an update to the 2014 review by Jain and Glauser [https://doi.org/10.1111/epi.12478]) of 25 ASMs of interest (articles from 12 ASMs included) on the effect of ASMs/non-drug treatments on sleep in patients with epilepsy was conducted. The most common objective instrument was polysomnography, and the most common subjective measures were the Epworth Sleepiness Scale and the Pittsburgh Sleep Quality Index. Eslicarbazepine acetate, lacosamide, and perampanel improved or had no effect on sleep. Perampanel was associated with low incidence of insomnia, and lacosamide with low incidence of daytime sleepiness adverse events. Clonazepam, felbamate, lamotrigine, oxcarbazepine, and phenobarbital worsened or had no effect on sleep. Lamotrigine may be associated with insomnia risk and phenobarbital with daytime sleepiness. Data for valproic acid were mixed. Overall, cannabidiol, carbamazepine, and levetiracetam had no effect on sleep. Epilepsy surgery may benefit sleep in patients with a good surgical outcome. Some ASMs, and, possibly, epilepsy surgery, may have positive effects on sleep, possibly linked to achieving seizure control. Nonetheless, other ASMs may worsen sleep in some settings. Clinicians should consider such observations when making treatment decisions, particularly for patients with comorbid sleep disorders.